Portfolio Companies

Sort By:

Affini-T orchestrates the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.

×
Oncology | Preclinical | Active

Affini-T orchestrates the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.

Visit Site

Discovering & developing innovative therapies for disorders of the brain and nervous system.

IPO - Jun 2018
×
Neurology | Clinical | IPO
IPO - Jun 2018

Discovering & developing innovative therapies for disorders of the brain and nervous system.

Visit Site

Developing a proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose.

×
Rare Disease | Preclinical |

Developing a proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose.

Visit Site

Developing first-in-class CAR-macrophage platform for oncology and non-oncology applications.

×
Oncology | Clinical | Active

Developing first-in-class CAR-macrophage platform for oncology and non-oncology applications.

Visit Site
×

Cyrus solves difficult protein engineering and structure prediction problems using the most scientifically advanced, powerful, and laboratory-proven software.

×
Rare Disease, Immunology | Preclinical |

Cyrus solves difficult protein engineering and structure prediction problems using the most scientifically advanced, powerful, and laboratory-proven software.

Visit Site

Developing innovative medicines in immunology.

IPO - Sep 2021
×
Oncology, Immunology | Preclinical | IPO
IPO - Sep 2021

Developing innovative medicines in immunology.

Visit Site

Harnessing the immune system for improved patient outcomes using a targeted approach.

×
Oncology, Immunology | Clinical | Active

Harnessing the immune system for improved patient outcomes using a targeted approach.

Visit Site

Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases.

IPO - Oct 2021
×
Rare Disease | Preclinical | IPO
IPO - Oct 2021

Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases.

Visit Site
×

Pioneering the most comprehensive multiomics platform for early cancer detection.

×
Oncology | Clinical | Active

Pioneering the most comprehensive multiomics platform for early cancer detection.

Visit Site

Broadly applicable biologics platform across  many different therapeutic areas.

×
Rare Disease, Oncology, Immunology | Preclinical |

Broadly applicable biologics platform across  many different therapeutic areas.

Visit Site

Exploring uncharted territories in immunomodulation comprising Butyrophilins & Gamma-delta T cells.

×
Oncology | Clinical | Active

Exploring uncharted territories in immunomodulation comprising Butyrophilins & Gamma-delta T cells.

Visit Site

Developing targeted therapeutics for complex diseases using novel single cell analyses.

×
Oncology, Immunology | Preclinical | Active

Developing targeted therapeutics for complex diseases using novel single cell analyses.

Visit Site
×

Gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.

×
Oncology | Preclinical | Active

Gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.

Visit Site

Preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems.

×
Rare Disease, Immunology | Preclinical |

Preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems.

Visit Site

Discovering breakthrough gene editing systems for curing disease.

×
Rare Disease, Oncology, Immunology | Preclinical | Active

Discovering breakthrough gene editing systems for curing disease.

Visit Site

Developing therapeutics for rare cancers, including anaplastic astrocytoma.

×
Oncology | Clinical | Active

Developing therapeutics for rare cancers, including anaplastic astrocytoma.

Visit Site
×

Developing gene therapies for rare immunology disorders.

IPO - Nov 2018
×
Rare Disease, Neurology, Immunology | Commercial | IPO
IPO - Nov 2018

Developing gene therapies for rare immunology disorders.

Visit Site

Developing therapeutics for rare dermatological disorders.

×
Rare Disease, Immunology | Clinical | Active

Developing therapeutics for rare dermatological disorders.

Visit Site

Targeting a range of fibrotic diseases, with a focus on fibrotic tissue-specific inhibition of integrins.

IPO - Jun 2020
×
Rare Disease | Clinical | IPO
IPO - Jun 2020

Targeting a range of fibrotic diseases, with a focus on fibrotic tissue-specific inhibition of integrins.

Visit Site

Gene-editing platform to overcome cancers, cure genetic diseases, and enable development of safer food.

IPO - Apr 2019
×
Rare Disease, Oncology | Clinical | IPO
IPO - Apr 2019

Gene-editing platform to overcome cancers, cure genetic diseases, and enable development of safer food.

Visit Site
×

Charting a course to therapeutics for difficult-to-treat cancers.

IPO - Oct 2021
×
Oncology | Preclinical | IPO
IPO - Oct 2021

Charting a course to therapeutics for difficult-to-treat cancers.

Visit Site

Small molecule platform company for alternative modulation of RNA.

×
Rare Disease, Oncology, Neurology | Preclinical | Active

Small molecule platform company for alternative modulation of RNA.

Visit Site

Applying an all-in-human, artificial intelligence powered drug discovery platform to unlock new drugs at scale.

×
| |

Applying an all-in-human, artificial intelligence powered drug discovery platform to unlock new drugs at scale.

Visit Site

Overcoming current limitations of CAR-T cell therapeutics by using combining cell and gene editing technologies that address unmet patient need.

×
Oncology | Preclinical | Active

Overcoming current limitations of CAR-T cell therapeutics by using combining cell and gene editing technologies that address unmet patient need.

Visit Site
×

Bringing best-in-class immune-based therapies to patients in need.

×
Immunology | Clinical | Active

Bringing best-in-class immune-based therapies to patients in need.

Visit Site